A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Clinical trial NCT04606771 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04606771
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2020-09-28
Primary completion: 2022-12-21
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.